Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Analyst Ratings
Strong Buy
16 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
REGN Stock 12 Month Forecast
Average Price Target
$929.32
▲(66.57% Upside)
| Highest Price Target$1,152 | Average Price Target$929.32 | Lowest Price Target$575.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
Reiterated
04/14/25
Goldman Sachs
Reiterated
04/11/25
Citi
Reiterated
04/11/25
Guggenheim
Reiterated
04/10/25
Bank of America Securities
Reiterated
04/09/25
Morgan Stanley
Reiterated
04/09/25
Bernstein
Reiterated
04/03/25
RBC Capital
Reiterated
04/03/25
Oppenheimer
Reiterated
04/03/25
Wells Fargo
Reiterated
04/02/25
J.P. Morgan
$1,100→$1,000
Buy
79.24%
Upside
Reiterated
03/31/25
Regeneron price target lowered to $1,000 from $1,100 at JPMorganRegeneron price target lowered to $1,000 from $1,100 at JPMorgan
UBS
$768
Hold
37.66%
Upside
Reiterated
03/14/25
Eylea biosimilar injunction denial 'negative' for Regeneron, says UBSEylea biosimilar injunction denial 'negative' for Regeneron, says UBS
BMO Capital
$950→$903
Buy
61.85%
Upside
Reiterated
03/14/25
Regeneron: Positioned for Growth Amidst Challenges with a Promising Pipeline and Catalyst-Rich Future
TD Cowen
$970
Buy
73.86%
Upside
Reiterated
03/06/25
TD Cowen Sticks to Their Buy Rating for Regeneron (REGN)
Canaccord Genuity
$1,152
Buy
106.48%
Upside
Reiterated
02/25/25
Promising Developments and Strategic Positioning Justify Buy Rating for RegeneronWe expect DB-OTO could be approved based on ~n=20 or fewer patients, with regulatory submission expected YE25. We estimate DB-OTO pricing could be notable, given the potential for the drug to reverse hearing loss in young children. Maintain BUY, $1,152 price target We maintain our BUY rating and $1,152 price target for Regeneron. We believe DB-OTO is promising as an ultra-orphan therapy, and do not currently include the program in our estimates. Overall, we continue to look for the switch to EYLEA HD to accelerate, and for EYLEA 2 mg competition to stabilize. We also look for REGN’s Factor XI program and other pipeline assets to offset pressure on EYLEA revenues.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
Reiterated
04/14/25
Goldman Sachs
Reiterated
04/11/25
Citi
Reiterated
04/11/25
Guggenheim
Reiterated
04/10/25
Bank of America Securities
Reiterated
04/09/25
Morgan Stanley
Reiterated
04/09/25
Bernstein
Reiterated
04/03/25
RBC Capital
Reiterated
04/03/25
Oppenheimer
Reiterated
04/03/25
Wells Fargo
Reiterated
04/02/25
J.P. Morgan
$1,100→$1,000
Buy
79.24%
Upside
Reiterated
03/31/25
Regeneron price target lowered to $1,000 from $1,100 at JPMorganRegeneron price target lowered to $1,000 from $1,100 at JPMorgan
UBS
$768
Hold
37.66%
Upside
Reiterated
03/14/25
Eylea biosimilar injunction denial 'negative' for Regeneron, says UBSEylea biosimilar injunction denial 'negative' for Regeneron, says UBS
BMO Capital
$950→$903
Buy
61.85%
Upside
Reiterated
03/14/25
Regeneron: Positioned for Growth Amidst Challenges with a Promising Pipeline and Catalyst-Rich Future
TD Cowen
$970
Buy
73.86%
Upside
Reiterated
03/06/25
TD Cowen Sticks to Their Buy Rating for Regeneron (REGN)
Canaccord Genuity
$1,152
Buy
106.48%
Upside
Reiterated
02/25/25
Promising Developments and Strategic Positioning Justify Buy Rating for RegeneronWe expect DB-OTO could be approved based on ~n=20 or fewer patients, with regulatory submission expected YE25. We estimate DB-OTO pricing could be notable, given the potential for the drug to reverse hearing loss in young children. Maintain BUY, $1,152 price target We maintain our BUY rating and $1,152 price target for Regeneron. We believe DB-OTO is promising as an ultra-orphan therapy, and do not currently include the program in our estimates. Overall, we continue to look for the switch to EYLEA HD to accelerate, and for EYLEA 2 mg competition to stabilize. We also look for REGN’s Factor XI program and other pipeline assets to offset pressure on EYLEA revenues.
Best Analysts Covering Regeneron
Which Analyst Should I Follow If I Want to Buy REGN and Sell After:
1 Month
xxx
Success Rate
23/41 ratings generated profit
Average Return
+1.11%
assigned a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.10% of your transactions generating a profit, with an average return of +1.11% per trade.
3 Months
xxx
Success Rate
11/19 ratings generated profit
Average Return
+1.38%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +1.38% per trade.
1 Year
Success Rate
13/19 ratings generated profit
Average Return
+12.48%
reiterated a buy rating 2 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +12.48% per trade.
2 Years
xxx
Success Rate
13/19 ratings generated profit
Average Return
+14.03%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.42% of your transactions generating a profit, with an average return of +14.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
REGN Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
7
17
21
17
12
Buy
31
21
17
19
12
Hold
9
11
9
8
4
Sell
2
3
3
2
2
Strong Sell
0
0
0
0
0
total
49
52
50
46
30
Each month's total comprises the sum of three months' worth of ratings.
REGN Financial Forecast
REGN Stock Forecast FAQ
What is REGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron’s 12-month average price target is $929.32.
What is REGN’s upside potential, based on the analysts’ average price target?
Regeneron has 66.57% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is REGN a Buy, Sell or Hold?
Regeneron has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 1 sell ratings.
What is Regeneron’s price target?
The average price target for Regeneron is $929.32. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,152.00 ,the lowest forecast is $575.00. The average price target represents 66.57% Increase from the current price of $557.91.
The highest analyst price target is $1,152.00 ,the lowest forecast is $575.00. The average price target represents 66.57% Increase from the current price of $557.91.
What do analysts say about Regeneron?
Regeneron’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of REGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.